TG THERAPEUTICS, INC. Interest Expense Nonoperating
TG THERAPEUTICS, INC. (TGTX) reported Interest Expense Nonoperating of $16.57 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- TG THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $16.57M, a 146.75% increase year-over-year.
- TG THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $7.67M, a 13.45% increase year-over-year.
- TG THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $6.53M, a 7.48% decline year-over-year.
- TG THERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $6.72M, a 37.95% decline year-over-year.
- TG THERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $26.73M, a 11.23% increase from fiscal 2024.
- TG THERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $24.03M, a 90.47% increase from fiscal 2023.
- TG THERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $12.62M, a 23.79% increase from fiscal 2022.
- TG THERAPEUTICS, INC. interest expense nonoperating for fiscal 2022 was $10.19M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.57M 10-Q · filed 2026-08-05 | $24.24M 10-Q · filed 2026-08-05 | $30.77M derived: sum of 3 quarters · filed 2026-08-05 | $37.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.67M 10-Q · filed 2026-05-06 | $14.20M derived: sum of 2 quarters · filed 2026-05-06 | $20.92M derived: sum of 3 quarters · filed 2026-05-06 | $27.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $13.25M derived: sum of 2 quarters · filed 2026-02-27 | $19.97M derived: sum of 3 quarters · filed 2026-08-05 | $26.73M 10-K · filed 2026-02-27 |
| 2025-09-30 | $6.72M 10-Q · filed 2025-11-05 | $13.44M derived: sum of 2 quarters · filed 2026-08-05 | $20.19M 10-Q · filed 2025-11-05 | $27.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.72M 10-Q · filed 2026-08-05 | $13.47M 10-Q · filed 2026-08-05 | $20.53M derived: sum of 3 quarters · filed 2026-08-05 | $31.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.76M 10-Q · filed 2026-05-06 | $13.82M derived: sum of 2 quarters · filed 2026-05-06 | $24.65M derived: sum of 3 quarters · filed 2026-05-06 | $28.63M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $17.89M derived: sum of 2 quarters · filed 2026-02-27 | $21.87M derived: sum of 3 quarters · filed 2026-02-27 | $24.03M 10-K · filed 2026-02-27 |
| 2024-09-30 | $10.83M 10-Q · filed 2025-11-05 | $14.81M derived: sum of 2 quarters · filed 2025-11-05 | $16.97M 10-Q · filed 2025-11-05 | $19.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $3.98M 10-Q · filed 2025-08-08 | $6.26M 10-Q · filed 2025-08-08 | $8.70M derived: sum of 3 quarters · filed 2026-02-27 | $12.41M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $2.29M 10-Q · filed 2025-05-09 | $4.72M derived: sum of 2 quarters · filed 2026-02-27 | $8.43M derived: sum of 3 quarters · filed 2026-02-27 | $12.06M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.14M derived: sum of 2 quarters · filed 2026-02-27 | $9.77M derived: sum of 3 quarters · filed 2026-02-27 | $12.62M 10-K · filed 2026-02-27 |
| 2023-09-30 | $3.71M 10-Q · filed 2024-11-07 | $7.34M derived: sum of 2 quarters · filed 2024-11-07 | $10.18M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $3.63M 10-Q · filed 2024-08-09 | $6.47M 10-Q · filed 2024-08-09 | ||
| 2022-12-31 | $10.19M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |